US 11,866,490 B2
Antibody that binds to VEGF and IL-1beta and methods of use
Roland Beckmann, Penzberg (DE); Joerg Benz, Basel (CH); Stefan Dengl, Penzberg (DE); Christian Gassner, Penzberg (DE); Guido Hartmann, Basel (CH); Peter Michael Huelsmann, Penzberg (DE); Sabine Imhof-Jung, Penzberg (DE); Kristian Hobolt Jensen, Penzberg (DE); Hubert Kettenberger, Penzberg (DE); Stefan Lorenz, Penzberg (DE); Joerg Moelleken, Penzberg (DE); and Olaf Mundigl, Penzberg (DE)
Assigned to Hoffmann-La Roche Inc., Little Falls, NJ (US)
Filed by Hoffmann-La Roche Inc., Little Falls, NJ (US)
Filed on Sep. 8, 2021, as Appl. No. 17/469,044.
Application 17/469,044 is a division of application No. 16/722,317, filed on Dec. 20, 2019, granted, now 11,130,804.
Claims priority of application No. 18215023 (EP), filed on Dec. 21, 2018.
Prior Publication US 2022/0041707 A1, Feb. 10, 2022
Int. Cl. C07K 16/22 (2006.01); C07K 16/24 (2006.01); A61K 39/395 (2006.01)
CPC C07K 16/22 (2013.01) [C07K 16/245 (2013.01); A61K 39/39533 (2013.01); C07K 2317/31 (2013.01); C07K 2317/55 (2013.01); C07K 2317/565 (2013.01); C07K 2317/567 (2013.01); C07K 2317/92 (2013.01); C07K 2317/94 (2013.01)] 36 Claims
 
1. A method for decreasing the rate of ocular disease progression in an individual having the ocular disease, comprising administering to the individual a therapeutically effective amount of an antibody or antigen-binding fragment thereof that binds to human VEGF and to human IL-1beta, wherein the antibody comprises a VEGF paratope and an IL-1beta paratope within one cognate pair of a variable light chain domain (VL domain) and a variable heavy chain domain (VH domain), wherein the VEGF paratope comprises amino acid residues from CDR-H2, CDR-L1 and CDR-L3 of the antibody that binds to human VEGF, wherein the IL-1beta paratope comprises amino acid residues from the CDR-H1, CDR-H3 and CDR-L2 of the antibody that binds to human IL-1beta, wherein the antibody or antigen-binding fragment thereof comprises a VH domain comprising (a) CDR-H1 comprising the amino acid sequence of SEQ ID NO: 13, (b) CDR-H2 comprising the amino acid sequence of SEQ ID NO: 14, and (c) CDR-H3 comprising the amino acid sequence of SEQ ID NO: 15, and a VL domain comprising (d) CDR-L1 comprising the amino acid sequence of SEQ ID NO: 16, (e) CDR-L2 comprising the amino acid sequence of SEQ ID NO: 17, and (f) CDR-L3 comprising the amino acid sequence of SEQ ID NO: 8, and wherein the administering decreases the rate of ocular disease progression in the individual, wherein the ocular disease is selected from the group consisting of age-related macular degeneration (AMD), geographic atrophy (GA), macular degeneration, macular edema, diabetic macular edema (DME), retinopathy, and diabetic retinopathy (DR).